Capability
Regulatory strategy
When the pathway is not obvious, the work is to make the scientific and evidentiary logic obvious. We frame development programs—meetings, endpoints, and benefit–risk—so agencies and boards can follow the thread from mechanism to labeled claims.
Novel modalities, digital measures, and first-in-class mechanisms strain legacy templates. Investors and partners ask for certainty; agencies ask for justified uncertainty. We help you hold both: a clear development and registration narrative with explicit risks, mitigations, and evidence milestones—before capital and timelines lock in.
The regulatory challenge
Biotechnology and medtech companies must make high-cost decisions under evolving guidance and heterogeneous international requirements. A pathway that looks feasible in a target product profile can unravel when nonclinical bridging is weaker than expected, when surrogate endpoints face skepticism, or when CMC maturity lags clinical acceleration. Boards and partners push for speed; agencies push for justified evidence. Without an explicit strategy, teams default to copying the last similar program—even when the science does not fit.
Strong regulatory strategy connects mechanism, patient need, trial design, and manufacturing readiness into a storyline reviewers can audit. It also connects outward to access: the same endpoints and comparators that satisfy FDA must often answer different questions for HTA. We build that integrated view early so you do not optimize for one gate and fail another.
Where we focus
Pathway selection and designation strategy
We evaluate routes—standard, expedited, De Novo, device-centric pathways where relevant—and the evidentiary bars each implies. That includes pediatric study planning, orphan considerations, and regenerative medicine designations where applicable. We document optionality: what must be true for Plan A, and what triggers a shift to Plan B without panic.
Evidence package architecture
We map nonclinical, clinical, biomarker, and real-world components into a coherent package: what each study is intended to prove, how uncertainty is bounded, and how residual risks are mitigated through pharmacovigilance or post-marketing commitments. For novel modalities we pay special attention to immunogenicity, durability, and long-term follow-up plans.
Agency engagement and meeting excellence
We craft briefing books, question lists, and simulation prep so cross-functional teams deliver one voice in Type B/C, INTERACT, pre-sub, and scientific advice settings. We maintain risk registers tied to meeting outcomes and feed agreed positions directly into development plans, protocols, and manufacturing roadmaps.
External narrative integrity
Investor decks and partner updates often drift ahead of the regulatory file. We align external messaging to the evidence you can actually generate—preserving credibility with capital markets while avoiding promises the development plan cannot keep.
What we deliver
- Pathway assessments with decision criteria, evidence gaps, and milestone-based governance.
- Integrated development plans connecting trials, CMC scale-up, and registration timing assumptions.
- Meeting packages, slide logic, and rehearsal facilitation for agency interactions.
- Benefit–risk framing memos suitable for internal governance and external Q&A.
- Regulatory sections for data rooms, licensing discussions, and IPO or follow-on financing.
- Handoffs to clinical program design, protocol development, and access strategy with explicit dependencies.
Outcomes you can expect
- Clearer trade-offs between speed, cost, and probability of regulatory success.
- Fewer surprises in agency meetings because questions and contingencies were pre-socialized internally.
- Stronger alignment between clinical, CMC, and stats on what “ready to file” means.
- External narratives that withstand diligence because they match the actual evidence plan.
How we work
Regulatory approval is rarely a single pivotal table; it is a constellation of evidence and judgment calls. lotor lab spends time on the “why this should be approvable” spine before drowning in template detail. We connect regulatory choices to payer and HTA implications so you do not win a label that cannot be reimbursed.
We work as an extension of your regulatory and medical leadership—supplementing, not supplanting, your RA leads and consultants. Our value is integrative: connecting siloed expertise into one storyline agencies and boards can follow.
When teams bring us in
- IND-enabling and pre-IND phases, when the registration path is still plastic.
- Before high-stakes meetings or submissions, to unify messaging and contingency plans.
- After unexpected feedback, clinical holds, or CRLs, to rebuild a credible path forward.
- Financing or BD events requiring a regulatory story that survives expert review.